**Table 1. Baseline and procedural characteristics and laboratory data in patients with severe lower extremity arterial diseases**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  **No Afib** |  **With Afib** |  **P** |
|  |  **N = 194** |  **N = 28** |  |
|  **Age (years)** | **72.6**  |  **(11.5)** | **80.6** | **(9.1)** | **0.001** |
|  **Male gender** | **107**  |  **55.2%** | **12** | **42.9%** | **0.232** |
|  **Body mass index (kg/m2)** | **23.8**  |  **(4.2)** | **22.8** | **(3.9)** | **0.252** |
|  **Heart rate at baseline (beats per minute)** | **87.4**  |  **(17.2)** | **90.7** | **(19.6)** | **0.349** |
|  **Systolic BP at baseline (mm Hg)** | **148.9**  |  **(31.1)** | **141.8** | **(27.8)** | **0.253** |
|  **Diastolic BP at baseline (mm Hg)** | **75.6**  |  **(14.3)** | **73.6** | **(13.1)** | **0.472** |
|  **Current/past smoker** | **49**  |  **25.3%** | **4** | **14.2%** | **0.275** |
|  **Alcohol intake** | **62**  |  **31.9%** | **7** | **25.0%** | **0.678** |
|  **Family history of premature CAD** | **2** |  **1%** | **0** | **0%** | **1.000** |
|  **History of hypertension** | **124**  |  **63.9%** | **21** | **75.0%** | **0.293** |
|  **History of diabetes mellitus** | **133**  |  **68.6%** | **17** | **60.7%** | **0.398** |
|  **History of insulin use** | **27** |  **13.9%** | **1** | **3.6%** | **0.218** |
|  **History of dyslipidemia** | **42** |  **21.6%** | **4** | **14.3%** | **0.461** |
|  **History of kidney disease** |  |  |  |  | **0.011** |
| **Normal kidney function** | **117** |  **60.3%** | **24** | **85.7%** |  |
|  **Chronic kidney disease** | **32** |  **16.5%** | **4** | **14.3%** |  |
|  **End-stage renal disease** | **45** |  **23.2%** | **0** | **0** |  |
|  **History of CAD** | **81** |  **41.8%** | **9** | **32.1%** | **0.412** |
|  **History of myocardial infarction** | **12** |  **6.2%** | **2** | **7.1%** | **0.692** |
|  **History of chronic heart failure** |  |  |  |  | **0.684** |
|  **NYHA class I** | **8** |  **4.1%** | **2** | **7.1%** |  |
|  **NYHA class II** | **10** |  **5.2%** | **2** | **7.1%** |  |
|  **NYHA class III** | **12** |  **6.2%** | **3** | **10.7%** |  |
|  **NYHA class IV** | **5** |  **2.6%** | **0** | **0%** |  |
|  **History of carotid artery stenosis** | **3** |  **1.5%** | **0** | **0%** | **1.000** |
|  **History of ischemic stroke** | **27** |  **13.9%** | **8** | **28.6%** | **0.056** |
|  **History of any cancer** | **10**  |  **5.2%** | **3** | **10.7%** | **0.216** |
|  **History of amputation** | **13** |  **6.7%** | **0** | **0%** | **0.949** |
|  **Above-knee amputation** | **6** |  **3.1%** | **0** | **0%** |  |
|  **Below-knee amputation** | **3** |  **1.5%** | **0** | **0%** |  |
|  **Forefoot amputation** | **4** |  **2.1%** | **0** | **0%** |  |
|  **Presented with acute ischemic limb** | **21** |  **10.8%** | **7** | **25.0%** | **0.035** |
|  **Rutherford classification** |  |  |  |  | **0.663** |
|  **Class III** | **23** | **11.9%** | **2** | **7.1%** |  |
|  **Class IV** | **45** |  **23.2%** | **9** | **32.1%** |  |
|  **Class V** | **114** |  **58.8%** | **16** | **57.1%** |  |
| **Class VI** | **12** |  **6.2%** | **1** | **3.6%** |  |
| **CHADS2 score** | **2.2** |  **(1.2)** | **2.9** | **(1.3)** | **0.004** |
| **Laboratory data** |  |  |  |  |  |
|  **Total cholesterol (mg/dl)** | **160**  |  **(47.0)** | **148.0** | **(37.0)** | **0.204** |
|  **High-density lipoprotein cholesterol (mg/dl)** | **40.0**  |  **(16.0)** | **42.0** | **(27.0)** | **0.815** |
|  **Low-density lipoprotein cholesterol (mg/dl)** | **95.0**  |  **(37.0)** | **93.0** | **(30.0)** | **0.902** |
|  **Triglyceride (mg/dl)** | **158.0**  |  **(125.0)** | **105.0** | **(67.0)** | **0.033** |
|  **Fasting glucose (mg/dl)** | **176.0**  |  **(99.0)** | **177.0** | **(116.0)** | **0.965** |
|  **Glycosylated hemoglobin (%)** | **7.3**  |  **(1.9)** | **7.9** | **(2.1)** | **0.257** |
|  **Creatinine (mg/dl)** | **3.7**  |  **(3.5)** | **1.8** | **(1.1)** | **<0.001** |
|  **Creatinine clearance (ml/min)** | **34.1** | **(31.0)** | **33.3** | **(19.4)** | **0.852** |
|  **Estimated glomerular filtration rate (ml/min/1.732)**  | **41.6** | **(37.0)** | **46.2** | **(28.7)** | **0.448** |
|  **Alanine transaminase (IU/L)** | **22.0**  |  **(19.0)** | **30.0** | **(31.0)** | **0.150** |
|  **Uric acid (mg/dl)** | **5.7**  |  **(2.2)** | **6.8** | **(2.9)** | **0.022** |
|  **White blood cell count 103/*µ*l** | **9645** |  **(4970)** | **8593** | **(4623)** | **0.029** |
|  **Neutrophil ratio (%)** | **70.5** |  **(13.3)** | **67.7** | **(17.4)** | **0.330** |
|  **Lymphocyte ratio (%)** | **17.1** |  **(10.1)** | **17.0** | **(8.4)** | **0.969** |
|  **NLR** | **7.9**  |  **(10.0)** | **6.3** | **(6.4)** | **0.421** |
|  **Medication use at baseline** |  |  |  |  |  |
|  **Aspirin** | **70** |  **36.1%** | **12** | **42.9%** | **0.533** |
|  **Cilostazol** | **93** |  **47.9%** | **15** | **53.6%** | **0.687** |
|  **Clopidogrel** | **57** |  **29.4%** | **4** | **14.3%** | **0.115** |
|  **Oral anti-coagulants** | **0** |  **0%** | **7** | **25.0%** | **<0.001** |
|  **Pentoxifylline** | **8** |  **4.1%** | **3** | **10.7%** | **0.148** |
|  **ACEI or ARB** | **9** |  **4.6%** | **2** | **7.1%** | **0.634** |
|  **Beta-blocker** | **33** |  **17.0%** | **6** | **21.4%** | **0.596** |
|  **Calcium channel blocker** | **39** |  **20.1%** | **9** | **32.1%** | **0.149** |
|  **Statin** | **42** |  **21.6%** | **2** | **7.1%** | **0.080** |
|  **Urate lowering therapy** | **3** |  **1.5%** | **2** | **7.1%** | **0.121** |

**Values are expressed as numbers (standard deviation) or numbers and percentages.**

**Afib = atrial fibrillation; CAD = coronary artery disease; NYHA = New York Heart Association; BP = blood pressure; NLR = neutrophil-to-lymphocyte ratio; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker**